Paul Rubin

Former President & Chief Executive Officer at Chiesi USA, Inc.

Paul Rubin

Paul Rubin

Former President & Chief Executive Officer at Chiesi USA, Inc.

Overview
Career Highlights

Chiesi USA, Inc.
Resolvyx Pharmaceuticals, Inc.
Critical Therapeutics, Inc.

RelSci Relationships

1346

Number of Boards

3

Birthday

1954

Age

66

Contact Data
Trying to get in touch with Paul Rubin? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Paul Rubin likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Operating Officer at Orchard Therapeutics Plc

Relationship likelihood: Strong

Executive Director, Chief Operating Officer at Vectura Group Plc

Relationship likelihood: Strong

Physician & Pediatrician at The Massachusetts General Hospital

Relationship likelihood: Strong

President & Chief Executive Officer at Veloxis Pharmaceuticals A/S

Relationship likelihood: Strong

Chief Financial Officer at Sanifit, Inc.

Relationship likelihood: Strong

Interim Chief Scientific Officer at Proteostasis Therapeutics, Inc.

Relationship likelihood: Strong

Former Secretary, Senior Vice President-Legal Affairs & General Counsel at AMAG Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Medical Officer at Frequency Therapeutics, Inc.

Relationship likelihood: Strong

Chief Financial Officer at Axial Biotherapeutics, Inc.

Relationship likelihood: Strong

Managing Director at HealthCare Ventures LLC

Relationship likelihood: Strong

Paths to Paul Rubin
Potential Connections via
Relationship Science
You
Paul Rubin
Former President & Chief Executive Officer at Chiesi USA, Inc.
Education
MD
Class of 1979

Rush Medical College is a school.

BA
Class of 1975

In 1887, the year a group of knowledge-thirsty Presbyterians founded "The Occidental University of Los Angeles, California," a Kansas prohibitionist named Harvey Wilcox purchased a ranch just west of the city, naming it Hollywood. Tuition in 1888, the year Oxy opened its doors, was $50. The new college wasn't exactly swamped with applicants: 40 students enrolled that fall. Southern California's oldest football rivalry? Not UCLA-USC. Oxy and Pomona first squared off in 1895 -- preceding those other guys by more than 30 years. Student body president Clarence Spaulding became Oxy's first Rhodes Scholar in 1908. Today, Oxy still has more Rhodes Scholars (10) than USC (9). Big changes came to campus in 1926: freshmen were required to live on campus for the first time, and the Oxy basketball team had to adjust to playing indoors after Alumni Gymnasium was built. Sammy Lee '43's first gold medal in diving at the 1948 London Games wasn't Oxy's first Olympic hardware: Tigers have won a total of seven medals. If Oxy were a country, we'd be tied with Israel and Tunisia. In 1992, with the nation's eyes on Los Angeles during the largest riots the country had seen since the '60s, Occidental was recognized on the front page of The Wall Street Journal for its forward-thinking stance on diversity. A knight who hits people with a chicken? A commanding officer of a naval base and the Girl Scouts? The James Dean of disability studies? There are some brilliant characters among our notable alumni.

Internal Medicine Training

The University of Wisconsin School of Medicine and Public Health (UWSMPH) is a professional school for the study of medicine and public health at the University of Wisconsin–Madison. It is one of only two medical schools in Wisconsin, along with the Medical College of Wisconsin in Milwaukee, and the only public one.

Career History
President & Chief Executive Officer
? - 2006

Cornerstone Therapeutics, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for the hospital, rare disease and adjacent specialty care settings. It acquires, develops and commercializes prescription pharmaceutical drugs. The company was founded on October 31, 2008 and is headquartered in Cary, NC.

Executive Vice President, Research & Development
2017 - 2019

Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Executive Vice President of Research & Development
2016 - Prior

miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO.

Boards & Committees
Director
1997 - Prior

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Trustee
Prior

In 1887, the year a group of knowledge-thirsty Presbyterians founded "The Occidental University of Los Angeles, California," a Kansas prohibitionist named Harvey Wilcox purchased a ranch just west of the city, naming it Hollywood. Tuition in 1888, the year Oxy opened its doors, was $50. The new college wasn't exactly swamped with applicants: 40 students enrolled that fall. Southern California's oldest football rivalry? Not UCLA-USC. Oxy and Pomona first squared off in 1895 -- preceding those other guys by more than 30 years. Student body president Clarence Spaulding became Oxy's first Rhodes Scholar in 1908. Today, Oxy still has more Rhodes Scholars (10) than USC (9). Big changes came to campus in 1926: freshmen were required to live on campus for the first time, and the Oxy basketball team had to adjust to playing indoors after Alumni Gymnasium was built. Sammy Lee '43's first gold medal in diving at the 1948 London Games wasn't Oxy's first Olympic hardware: Tigers have won a total of seven medals. If Oxy were a country, we'd be tied with Israel and Tunisia. In 1992, with the nation's eyes on Los Angeles during the largest riots the country had seen since the '60s, Occidental was recognized on the front page of The Wall Street Journal for its forward-thinking stance on diversity. A knight who hits people with a chicken? A commanding officer of a naval base and the Girl Scouts? The James Dean of disability studies? There are some brilliant characters among our notable alumni.

Transactions
Details Hidden

miRagen Therapeutics, Inc. (Inactive) raised money in a private placement transaction

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Paul Rubin. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Paul Rubin's profile does not indicate a business or promotional relationship of any kind between RelSci and Paul Rubin.